Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand.
Yvonne H W DerksMelline G M SchilhamMark RijpkemaEsther M M SmeetsHelene I V Amatdjais-GroenenAnnemarie KipSanne A M van LithJill van de KampJ P Michiel SedelaarDiederik M SomfordMichiel SimonsPeter LavermanMartin GotthardtDennis W P M LöwikSandra HeskampSusanne LütjePublished in: European journal of nuclear medicine and molecular imaging (2023)
This study showed the feasibility of PSMA-N064-mediated tPDT in cell assays, a xenograft model and excised fresh human PCa tissue. This paves the way to investigate the impact of in vivo PSMA-tPDT on surgical outcome in PCa patients.
Keyphrases
- pet ct
- photodynamic therapy
- prostate cancer
- pet imaging
- end stage renal disease
- endothelial cells
- newly diagnosed
- ejection fraction
- fluorescence imaging
- chronic kidney disease
- single cell
- radical prostatectomy
- prognostic factors
- patient reported outcomes
- computed tomography
- cell therapy
- positron emission tomography
- bone marrow
- patient reported
- mass spectrometry
- mesenchymal stem cells